Las Vegas, NV -- (SBWIRE) -- 12/19/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Semtech Corporation(NASDAQ:SMTC), Trina Solar Limited (ADR)(NYSE:TSL) , ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC), CEL-SCI Corporation (NYSEMKT:CVM)
Semtech Corporation(NASDAQ:SMTC) decreased -13.57% at the price of $24.26 recently on a traded volume of 2.74 million shares, in comparison to 582,350.00 shares of average trading volume. So far this year, the stock is down over -16.1%.
The company has a total market capitalization of $2.74 million and its total outstanding shares are 68.64 million. Semtech Corporation (Semtech) is a supplier of analog and mixed-signal semiconductor products. Semtech designs, produces and markets a range of products that are sold principally into applications within the high-end consumer, industrial, computing and communications end-markets. Its product lines include protection products, advanced communications products, power management and high-reliability products and wireless and sensing products.
Has SMTC Found The Bottom and Ready To Move Up? Find Out Here
Trina Solar Limited (ADR)(NYSE:TSL) soared 3.24% at the trading price of $13.69 on a traded volume of 2.10 million shares till now, whereas its average trading volume is 5.82million shares. In the last three months, the stock is up 18.32%. The Intra-day range for the stock is $13.17 and $13.95. Trina Solar Limited (Trina Solar) is an integrated solar-power products manufacturer based in China with a global distribution network covering Europe, North America and Asia. The Company produces standard monocrystalline photovoltaic (PV) modules ranging from 165 Watts to 185 Watts in power output and multicrystalline PV modules ranging from 215 Watts to 240 Watts in power output.
For How Long TSL Gloss will Attract Investors? Find out via this report
ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC) jumped up 0.04% at the $0.740 recently. So far in three months, the stock is down -73.08%. The 52-week range for the stock is $0.70 and $0.80. Its introductory price for the day was $0.71 with the overall traded volume of 1.79 million shares. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Will IMUC Continue To Move Higher? Find Out Here
CEL-SCI Corporation (NYSEMKT:CVM) after opening its shares at the price of $0.58, dropped -19.30% , its recent trading price was $0.573 for the day. The stock moved on a traded volume of 1.48 million shares, in comparison to 457,397.00 shares of average trading volume.
The 52-week range for the stock is $0.53 and $3.09. Its introductory price for the day was $0.58. CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine.
Will CVM Get Buyers Even After The Recent Rally? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)